Diabetes

Finerenone was associated with a 20% lower risk of end-stage kidney disease among patients with T2D and CKD, according to authors of the FIDELITY analysis.

For individuals with A1c of 6.4-6.5%, just below the threshold for diabetes, risk of MACE was higher than for any other subgroup with A1c values ranging from 5.8-6.8%.

Among patients with diabetes, over 50% of statin users experienced diabetes progression vs 48% of non-statin users, according to a retrospective matched-cohort study.

EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.

EASD 2021: First analysis of its kind found COVID-19-induced lockdown was associated with improved glycemic control among patients with T1D, but not T2D.

This post-hoc analysis showed increased reductions in A1c, weight, and BP in T2D patients prescribed GLP-1 receptor agonists who were already taking an SGLT-2 inhibitor.

A pattern of nocturnal reverse-dipping blood pressure in persons with type 1 or 2 diabetes put them at more than twice the risk of all-cause mortality, according to new research.

EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.

EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.

From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

Citing data that show the incidence of type 2 diabetes increases at age 35 years, the Task Force now recommends the younger age to initiate screening vs the current age of 40 years.

The novel prandial insulin formulation from Eli Lilly is now approved for administration via continuous subcutaneous insulin infusion with an insulin pump.

The new indication for empagliflozin is to reduce risk of CV death and hospitalization for heart failure in patients with HFrEF,

Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.

Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.

Antidepressant therapy, used as prescribed, reduced risk for advanced complications of diabetes and death among more than 36 000 patients with comorbid diabetes and depression.

Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.

A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.

The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.